Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens

PHASE4RecruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

March 26, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Febrile Neutropenia
Interventions
DRUG

Ceftolozane-Tazobactam

In the intervention arm 3g of ceftolozane-tazobactam are given intravenously every 8 hours. Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.

DRUG

Meropenem

The comparator arm consists of 2g of meropenem given intravenously every 8 hours.Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.

Trial Locations (1)

Unknown

RECRUITING

A Beneficência Portuguesa de São Paulo, São Paulo

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Beneficência Portuguesa de São Paulo

OTHER